ReviewDrugs2005
Ertapenem: a review of its use in the treatment of bacterial infections.
Review in Drugs, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- Effectiveness of ertapenem for treatment of infections in children: An evidence mapping and meta-analysis.Frontiers in pediatrics · 2022Pooled it
- Carbapenems versus other beta-lactams in treating severe infections in intensive care: a systematic review of randomised controlled trials.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2008Pooled it
- Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia.Intensive care medicine · 2006Trial
- Detection of Helicobacter pylori (H. pylori) in resource limited area: a cross-sectional study.BMC infectious diseases · 2026Article
- Comparative Evaluation of Amoxicillin-Clavulanate and Ertapenem in an Exploratory Rat Model of ESBLBiomedicines · 2026Article
- A disproportionality analysis of adverse events associated with ertapenem using the FAERS database from 2004 to 2024.Scientific reports · 2025Article
- Progress in the Stereoselective Synthesis Methods of Pyrrolidine-Containing Drugs and Their Precursors.International journal of molecular sciences · 2024Review
- A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.Molecules (Basel, Switzerland) · 2023Review
- Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system.Frontiers in pharmacology · 2023Article
- Distribution of anaerobic bacteria and their sensitivity pattern to several antibiotics at the clinical microbiology laboratory of school of medicine, universitas Indonesia, Jakarta in 2019-2020.Iranian journal of microbiology · 2022Article
- Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012-2016.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- Risk factors associated with the development of seizures among adult patients treated with ertapenem: A matched case-control study.PloS one · 2017Observational
- Population Pharmacokinetics and Target Attainment of Ertapenem in Plasma and Tissue Assessed via Microdialysis in Morbidly Obese Patients after Laparoscopic Visceral Surgery.Antimicrobial agents and chemotherapy · 2017Article
- The Clinical Efficacy and Safety of Ertapenem for the Treatment of Complicated Urinary Tract Infections Caused by ESBL-Producing Bacteria in Children.International journal of nephrology · 2015Article
- Antianaerobic antimicrobials: spectrum and susceptibility testing.Clinical microbiology reviews · 2013Review
- New treatment options against gram-negative organisms.Critical care (London, England) · 2011Review
- Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm?Journal of medicinal chemistry · 2010Article
- Prolonged use of ertapenem to treat infected diabetic foot ulcers.Case reports in medicine · 2010Article
- Crystal structures of biapenem and tebipenem complexed with penicillin-binding proteins 2X and 1A from Streptococcus pneumoniae.Antimicrobial agents and chemotherapy · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Group 1, 1 beta-methyl carbapenem ertapenem (Invanz) is approved for parenteral use in patients with complicated intra-abdominal infection (cIAI), community-acquired pneumonia (CAP) and acute pelvic infection caused by susceptible strains of certain designated organisms in both the US and the EU. Additional approved indications in the US include complicated skin and skin structure infection (cSSSI) and complicated urinary tract infection (cUTI). Ertapenem is approved for use in adults in both the US and the EU and in paediatric patients aged >or=3 months in the US. Ertapenem has a broad spectrum of in vitro activity against Gram-negative pathogens, including extended-spectrum beta-lactamase (ESBL)- and AmpC-producing Enterobacteriaceae, Gram-positive pathogens and anaerobic pathogens. It has similar efficacy to comparator antibacterials such as piperacillin/tazobactam in cSSSI (including diabetic foot infection), cIAI and acute pelvic infection and ceftriaxone with or without metronidazole in cIAI, cUTI and CAP. The drug has also shown efficacy in the treatment of paediatric patients with complicated community-acquired bacterial infections. Ertapenem has a convenient once-daily administration schedule and is generally well tolerated. Thus, ertapenem is an important option for the empirical treatment of complicated community-acquired bacterial infections in hospitalised patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.